Zacks Rating on Synergy Pharmaceuticals (SGYP)

Synergy Pharmaceuticals (SGYP) has an average broker rating of 1, which is interpreted as a Strong Buy, as rated by 2 equity analysts. Nonetheless, 2 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold.

Synergy Pharmaceuticals (SGYP) : The most positive equity analysts on Synergy Pharmaceuticals (SGYP) expects the shares to touch $15, whereas, the least positive believes that the stock will trade at $7 in the short term. The company is covered by 2 Wall Street Brokerage Firms. The average price target for shares are $10.75 with an expected fluctuation of $6.01 from the mean.


Synergy Pharmaceuticals, Inc. has dropped 2.13% in the last five trading days, however, the shares have posted positive gains of 27.2% in the last 4 weeks. Synergy Pharmaceuticals, Inc. is up 42.66% in the last 3-month period. Year-to-Date the stock performance stands at -10.93%. Synergy Pharmaceuticals (NASDAQ:SGYP): On Tuesdays trading session , Opening price of the stock was $5.25 with an intraday high of $5.25. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $5.04. However, the stock managed to close at $5.05, a loss of 3.26% for the day. On the previous day, the stock had closed at $5.22. The total traded volume of the day was 2,724,177 shares.

Synergy Pharmaceuticals Inc. (Synergy) is a biopharmaceutical company focused on the development of drugs to treat gastrointestinal (GI), disorders and diseases. The Companys platform technology is based on the naturally occurring human GI peptide, uroguanylin, a regulator of normal GI physiology. The Companys products include plecanatide, SP-333 and FV-100. The Companys lead product is plecanatide, a guanylate cyclase C (GC-C), receptor agonist, designed to treat GI disorders, primarily chronic idiopathic constipation (CIC), and constipation predominant irritable bowel syndrome (IBS-C). The Company is developing a second-generation GC-C receptor agonist, SP-333, for the treatment of opioid induced constipation (OIC), and for inflammatory bowel disease (IBD). FV-100 is an orally available nucleoside analog. The Companys subsidiaries include Synergy Advanced Pharmaceuticals, Inc., IgX, Ltd and ContraVir Pharmaceuticals, Inc.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.